Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 1,404

Document Document Title
WO/1997/045441A1
The present invention relates to the novel 7'alpha'-(5-methylaminopentyl)-estratrienes of the general formula (I), in which R2 is a hydrogen or fluorine atom, R17 is a hydrogen atom, a methyl or ethynyl group, n is 2, 3 or 4, and x is 0,...  
WO/1997/038005A1
An antifungal and antilipemic agent comprising substance MK6059 of the following general formula (I) which is prepared by culturing a MK6059 strain belonging to the genus Ellisiodothis in a conventional nutrient medium for microbes, and ...  
WO/1997/031933A1
The present invention relates to novel ginseng saponin compounds having a potent anti-tumor activity, which are represented by formulae (I) and (II). The compounds (I) and (II) above are novel and can be produced by heating plants of gin...  
WO/1997/031013A1
This invention relates to ginsenoside Mc with formula (I), an intestinal flora metabolite of ginseng saponin and anticancer agent containing it as an active ingredient. In addition to a novel compound, the anticancer agent of this invent...  
WO/1997/027209A1
The invention relates to compounds of formula (I) in which R1, R2, R3, R4, R5, R6, X and n are as defined in the specification, and to pharmaceutical compositions containing them. These compounds are potent progestogens which are devoid ...  
WO/1997/024365A1
Compounds of the androstane series are described having general formula (I) and solvates thereof, in which R1 represents O, S or NH; R2 individually represents OC(=O)C1-6 alkyl; R3 individually represents hydrogen, methyl (which may be i...  
WO1997014696A3  
WO/1997/018824A1
The present invention relates to a vasodilating composition comprising ginsenoside Rg3 and/or Rg5, one of the saponin components of ginseng, as an active ingredient. Since ginsenoside Rg3 and Rg5, the active ingredient of the composition...  
WO/1997/014696A2
The invention concerns compounds of general formulae (Ia) and (Ib), in which R1 and R2, which may be identical or different, designate hydrogen, C1-C6 lower alkyl, straight-chain or branched, or an aryl group, optionally substituted by e...  
WO1996040043A3  
WO/1997/010256A1
Hitherto unknown compounds of formula (II) wherein R1 is hydrogen or methyl; R2 is hydrogen, methyl, CH2OH, CH2OR3, CHO, CH=CH2, COOH or COOR4; R3 is alkyl, aralkyl, aryl, alkanesulfonyl, arene-sulfonyl; alkanoyl or aroyl, optionally sub...  
WO/1996/040152A1
The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgica...  
WO/1996/040043A2
The invention relates to 3'alpha'-hydroxy, 17-(un)substituted derivatives of the androstane series and 3'alpha'-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified ...  
WO/1996/038466A1
The invention relates to certains steroidal glycoside derivatives useful as hypocholesterolemic agents and antiatherosclerosis agents. The present invention is also directed to pharmaceutical compositions comprising such derivatives and ...  
WO/1996/035707A1
The present invention is directed to steroidal or terpenoidal compounds which inhibit farnesyl-protein transferase (FPTase). The invention is further directed to chemotherapeutic compositions containing the compounds of this invention an...  
WO/1996/035432A1
There are disclosed novel compounds having formulae (I) and (II) which exhibit antifungal activity.  
WO/1996/035407A1
Alendronate, a bisphosphonate can prevent tooth loss not necessarily associated with periodontal disease. Preferably, alendronate (or a pharmaceutically acceptable salt thereof) is given daily for an extended period of time.  
WO/1996/026201A1
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility, and preferred stereoisomers are shown to be...  
WO/1996/003995A1
The present invention relates to methods for the treatment or prevention of osteoporosis and the alleviation of the symptoms of menopause by the administration of an estrogen glycoside or estrogen orthoester glycoside.  
WO/1996/003423A1
The invention concerns a method of producing hapten-marked peptides, characterized by the fact that (a) a peptide with the desired amino acid sequence is synthesised on a solid phase of amino acid derivatives whose reactive side groups a...  
WO/1996/001618A1
A dermatologic preparation comprising at least either an escinol represented by general formula (1) or a salt thereof and having an excellent skin-lightening effect and a high safety in virtue of characteristic effects of the escinol, wh...  
WO/1996/000230A1
The present invention relates to a process for the preparation and manufacture of 3-amino-substituted glycosylated bile acid derivatives. Novel intermediates and related compounds are also disclosed. In particular, the present invention ...  
WO/1995/032981A1
Novel steroidal and non-steroidal enopyranoside compounds, where the enopyranoside is acylated or deacylated, are provided. The steroid and non-steroidal enopyranosides possess the same pharmaceutical properties as their steroid and non-...  
WO/1995/029186A1
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...  
WO/1995/024415A1
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...  
WO/1995/021617A1
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.  
WO/1995/020393A1
The use of aerosolized particles of mometasone furoate for the preparation of medicaments in the form of dry powders, solutions, or aqueous suspension for once-a-day treating corticosteroid-responsive diseases of the surfaces of upper an...  
WO/1995/016699A1
To provide a novel antitumor steroid compound which can be synthesized efficiently and stereoselectively by the technique of organic synthetic chemistry. A steroid derivative represented by general formula (I) or a salt thereof, wherein ...  
WO/1995/011914A1
The present invention relates to 'DELTA'16 unsaturated C17 heterocyclic steroids which are useful as steroid C17-20 lyase inhibitors.  
WO/1995/010527A1
Novel di- and tri-methyl androst-5-ene-3,17-diols, having from 1 to 2 methyl substituents and optionally an hydroxyl group at the 7 position are provided. The compounds may be used prophylactically and therapeutically for activities asso...  
WO/1995/009177A1
A glycoside represented by formula (I), wherein dexamethasone or betamethasone is the aglycon and the 21-position is substituted by a simple sugar or an acylated sugar selected from the group consisting of glucose, galactose, mannose, rh...  
WO/1995/008557A1
The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of general formula (I), wherein: a) R1 is (i) COOR5, where R5 is hydrogen, a 1-6 carbo...  
WO/1994/027608A1
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3alpha-hydroxy-5-reduced steroid derivatives.  
WO1994016709A3  
WO/1994/020520A1
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...  
WO/1994/019366A1
Methods for the chemical preparation or synthesis of the sterol antibiotic squalamine. Preferably, the preparation is by modifying the 3-position of a 3-oxo-7alpha-hydroxy-24zeta-ether protected alcohol group-5alpha-cholestane with a spe...  
WO/1994/016709A2
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, dim...  
WO/1994/014451A1
A composition for the prevention of inflammatory or allergic reaction or the treatment of cardiovascular or haemodynamic disorders comprising a compound of formula (I), where R = (a), and the trans isomer of formula (II), where R = (b), ...  
WO/1994/011386A1
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...  
WO/1994/011004A1
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...  
WO1994006402A3  
WO/1994/006402A2
The invention relates to a cosmetic or dermatologic composition. Said composition contains as active ingredient a saponine having formula (I) wherein R1 is -Glc(2-1)Glc; R2 is -Glc(6-1)Glc; R3 is H. The saponine is called G-Rb1; Glc desi...  
WO/1994/005678A1
Compounds comprising a first aromatic ring linked to a xylose via a hydroxyl, thio, hydrocarbon, or amino substituent to form a beta-D-xyloside linkage and a second aromatic ring fused to the first ring are useful primers for the biosynt...  
WO/1994/005305A1
A human cataractous lens nuclei methanolic extract consists essentially of substances having a molecular weight lower than 3,000 daltons. The substances inhibit ATP hydrolysis by Na+, K+-ATPase and have affinity to the ouabain binding si...  
WO1993010741A3  
WO/1994/000479A1
A process for the synthesis of 1-O-steroidal-peracyl-beta-glycosides that provides greater beta-anomeric selectivity with reduced by-products and side reactions. The process comprises reacting heptaacyl-D-cellobiosyl-1-halide, tetraacyl-...  
WO/1993/023038A1
Novel amino substituted 4-azasteroid 5alpha-reductase inhibitors of formula (I), wherein A is (a), (b) or (c), are claimed as well as pharmaceutically acceptable salts and formulations thereof. These compounds are effective in inhibiting...  
WO/1993/022333A1
Invented are 17$g(a) and 17$g(b)-substituted acyl-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-$g...  
WO/1993/022334A1
Pharmaceutical compositions and methods are provided for the colon-specific delivery of corticosteroids (I). The corticosteroids are administered in the form of prodrugs which undergo reaction with enzymes produced by colonic microflora,...  
WO/1993/021198A1
Sialic acid derivatives of cortison, dexamethasone and vitamin D3 represented by general formula (I), wherein R1 represents a steroid residue selectd from among cortisone, dexamethasone and vitamin D3; R2 represents hydrogen or acetyl; a...  

Matches 251 - 300 out of 1,404